Actively Recruiting
Developing an Internationally-diverse, Linked Genomic and Longitudinal Phenotypic Research Dataset to Accelerate Precision Psychiatry for Patients With Serious Mental Illness
Led by Akrivia Health · Updated on 2025-10-03
50000
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
Sponsors
A
Akrivia Health
Lead Sponsor
C
Cardiff University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting an observational study to better understand severe mental illnesses such as schizophrenia, bipolar disorder, major depressive disorder, and dementias. This study aims to improve how these conditions are diagnosed and treated by collecting detailed biological and clinical information. By analyzing genetic data and other health records from over 50,000 participants, the study hopes to identify new ways to classify and predict outcomes for these challenging brain disorders. Participants will be grouped into three cohorts based on their condition and the type of biological samples they provide. About 40,000 participants will provide DNA samples via saliva or blood, 9,000 will provide additional blood samples including RNA and plasma, and 1,000 with dementia will provide similar extended blood samples. The study uses a digital portal for recruitment and sample collection, with options for remote or in-person participation to ensure diverse and inclusive involvement. During the study, participants' electronic health records will be linked with the biological data collected. Researchers will assess diagnoses within one month of sample collection and baseline assessments. The study also includes cognitive testing for dementia patients and ongoing monitoring of participant data quality and diversity. The data will be securely shared with other researchers to advance mental health research, with the study lasting until 2035.
CONDITIONS
Brief Title
Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All participants must have an electronic health record in a primary or secondary care service.
- Mental health participants must have a diagnosis or treatment/referral for major depressive disorder, bipolar disorder, or schizophrenia.
- Participants must be 18 years of age or older with no upper age limit.
- Participants must be able to speak English.
- Dementia participants must be currently alive, have been seen by old age psychiatry, and have a diagnosis or referral related to dementia, mild cognitive impairment, or subjective cognitive impairment.
- Dementia participants must be willing and able to complete a validated cognitive assessment (MoCA or SLUMS).
You will not qualify if you...
- Mental health participants who lack capacity to provide consent.
- Dementia participants unable to understand spoken or written English.
- Individuals with intellectual disability.
- Participants with dementia caused by Creutzfeldt-Jakob disease, Huntington's disease, HIV dementia, alcohol-related dementia, intellectual disability, or traumatic brain injury.
- Dementia participants with prior diagnoses of depression (for MCI/SCI patients only), psychosis, or bipolar disorder in the pre-index period.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (remote or in-person) for eligibility confirmation
Duration - Varies depending on cohort; sample collection occurs once
Participants provide biological samples and baseline assessments to collect DNA and other biomarkers, and their electronic health records are linked for research purposes.
1 to 2 visits depending on sample collection method (remote saliva kit or in-person blood draw)
Duration - Up to 10 years
Participants' health data from electronic health records are monitored longitudinally to support research on neuropsychiatric and neurodegenerative disorders.
No additional visits; ongoing data linkage and monitoring
Trial Site Locations
Total: 1 location
1
GlobalMinds central study team
Oxford, Oxford, United Kingdom, OX1 3HJ
Actively Recruiting
Research Team
S
Samantha Yuille, PhD
B
Byron Tibbitts
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here